{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:44:53Z","timestamp":1790279093852,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016348","name":"Kyowa Kirin Pharmaceutical Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Summary<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>In a United States claims database, 1,358 persons with familial hypophosphatemia who began treatment with burosumab were identified. Prior to treatment, high rates of several morbidities were coded including osteoarthritis, fractures, enthesopathy, spinal stenosis, hypertension, depression and opioid use, which generally increased with age, emphasizing disease burden throughout the lifespan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To examine the characteristics and disease history of real-world patients with X-linked hypophosphatemia (XLH) in the United States, prior to initiating burosumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study used Komodo Health\u2019s Healthcare Map\u2122, a de-identified patient-level claims database. Included patients had\u2009\u2265\u20091 claim for familial hypophosphatemia between 01-Jan-2015 and 30-Jun-2022 (the study period) and\u2009\u2265\u20091 claim for burosumab between 01-Apr-2018 and 30-Jun-2022. The index date was the date of first burosumab claim. Patient demographics were measured at index; disease history was measured over the pre-index period and stratified by age. All variables were evaluated descriptively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>1,358 patients were included (mean age 23.5\u2009\u00b1\u200919.1\u00a0years, 847 [62%] female); 720 patients (53%) were aged\u2009&lt;\u200918\u00a0years. Prior to index, patients had high levels of XLH-related morbidities. Most XLH-related morbidities appeared in the youngest age groups, and the prevalence was generally greater among the older age groups. For example, arthralgia was found in 57 patients (12%) aged\u2009\u2264\u200911\u00a0years and 123 patients (69%) aged\u2009\u2265\u200950\u00a0years. Opioid use increased with age (173 patients [24%] aged\u2009&lt;\u200918\u00a0years; 328 [51%]\u2009\u2265\u200918\u00a0years). Physical therapy use was observed across age groups (126 patients [18%] aged\u2009&lt;\u200918\u00a0years; 253 [40%]\u2009\u2265\u200918\u00a0years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>At initiation of burosumab, over half of patients with XLH were\u2009&lt;\u200918\u00a0years of age. Claims indicated a high prevalence of XLH-related morbidities, which began at a young age and increased over time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-025-01544-1","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T06:24:35Z","timestamp":1747117475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world characteristics &amp; disease history of patients with X-linked hypophosphatemia before treatment with burosumab"],"prefix":"10.1007","volume":"20","author":[{"given":"Kathryn M.","family":"Dahir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Heerssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Noman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.","family":"Imel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"10","key":"1544_CR1","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1530\/EC-20-0291","volume":"9","author":"R Padidela","year":"2020","unstructured":"Padidela R, Cheung MS, Saraff V, Dharmaraj P (2020) Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British Paediatric and Adolescent Bone Group recommendations. Endocr Connect 9(10):1051\u20131056. https:\/\/doi.org\/10.1530\/EC-20-0291","journal-title":"Endocr Connect"},{"issue":"3","key":"1544_CR2","doi-asserted-by":"publisher","first-page":"e1249","DOI":"10.1210\/clinem\/dgab739","volume":"107","author":"MK Javaid","year":"2022","unstructured":"Javaid MK, Ward L, Pinedo-Villaneuva R et al (2022) Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data. J Clin Endocrinol Metab 107(3):e1249\u2013e1262. https:\/\/doi.org\/10.1210\/clinem\/dgab739","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1544_CR3","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1210\/clinem\/dgz203","volume":"105","author":"S Hawley","year":"2020","unstructured":"Hawley S, Shaw NJ, Delmestri A et al (2020) Prevalence and mortality of individuals with X-linked hypophosphatemia: a United Kingdom real-world data analysis. J Clin Endocrinol Metab 105(3):e871-878. https:\/\/doi.org\/10.1210\/clinem\/dgz203","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1544_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM et al (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15(7):435\u2013455. https:\/\/doi.org\/10.1038\/s41581-019-0152-5","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"1544_CR5","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/js.2018-00365","volume":"3","author":"A Skrinar","year":"2019","unstructured":"Skrinar A, Dvorak-Ewell M, Evins A et al (2019) The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc 3(7):1321\u20131334. https:\/\/doi.org\/10.1210\/js.2018-00365","journal-title":"J Endocr Soc"},{"key":"1544_CR6","doi-asserted-by":"publisher","unstructured":"Dahir K, Roberts MS, Krolczyk S, Simmons JH (2020) X-linked hypophosphatemia: a new era in management. J Endocr Soc 4(12):bvaa151. https:\/\/doi.org\/10.1210\/jendso\/bvaa151","DOI":"10.1210\/jendso\/bvaa151"},{"issue":"3","key":"1544_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","volume":"160","author":"SS Beck-Nielsen","year":"2009","unstructured":"Beck-Nielsen SS, Brock-Jacobsen B, Gram J et al (2009) Incidence and prevalence of nutritional and hereditary rickets in Southern Denmark. Eur J Endocrinol 160(3):491\u2013497. https:\/\/doi.org\/10.1530\/EJE-08-0818","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1544_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EJE-15-0515","volume":"174","author":"S Rafaelsen","year":"2016","unstructured":"Rafaelsen S, Johansson S, R\u00e6der H, Bjerknes R (2016) Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol 174(2):125\u2013136. https:\/\/doi.org\/10.1530\/EJE-15-0515","journal-title":"Eur J Endocrinol"},{"key":"1544_CR9","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s11136-020-02465-x","volume":"29","author":"SH Lo","year":"2020","unstructured":"Lo SH, Lachmann R, Williams A et al (2020) Exploring the burden of x-linked hypophosphatemia: a European multi-country qualitative study. Qual Life Res 29:1883\u20131893. https:\/\/doi.org\/10.1007\/s11136-020-02465-x","journal-title":"Qual Life Res"},{"key":"1544_CR10","doi-asserted-by":"publisher","unstructured":"Cheung M, Rylands AJ, Williams A et al (2021) Patient-reported complications, symptoms, and experiences of living with X-linked hypophosphatemia across the life-course. J Endocr Soc 5(8):bvab070. https:\/\/doi.org\/10.1210\/jendso\/bvab070","DOI":"10.1210\/jendso\/bvab070"},{"issue":"6","key":"1544_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jbspin.2019.01.012","volume":"86","author":"A-S Lambert","year":"2019","unstructured":"Lambert A-S, Zhukouskaya V, Rothenbuhler A, Linglart A (2019) X-linked hypophosphatemia: management and treatment prospects. Joint Bone Spine 86(6):731\u2013738. https:\/\/doi.org\/10.1016\/j.jbspin.2019.01.012","journal-title":"Joint Bone Spine"},{"issue":"11","key":"1544_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40267-018-0560-9","volume":"34","author":"K Lyseng-Williamson","year":"2018","unstructured":"Lyseng-Williamson K (2018) Burosumab in X-linked hypophosphatemia: a profile of its use in the USA. Drugs Ther Perspect 34(11):497\u2013506. https:\/\/doi.org\/10.1007\/s40267-018-0560-9","journal-title":"Drugs Ther Perspect"},{"key":"1544_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bone.2019.06.025","volume":"127","author":"S DeLacey","year":"2019","unstructured":"DeLacey S, Liu Z, Broyles A et al (2019) Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients. Bone 127:386\u2013392. https:\/\/doi.org\/10.1016\/j.bone.2019.06.025","journal-title":"Bone"},{"issue":"7","key":"1544_CR14","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA et al (2011) A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res 26(7):1381\u20131388. https:\/\/doi.org\/10.1002\/jbmr.340","journal-title":"J Bone Miner Res"},{"key":"1544_CR15","unstructured":"US Food and Drug Administration (2018) US Food and Drug Administration approves first therapy for rare inherited forms of rickets, X-linked hypophosphataemia. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-therapy-rare-inherited-form-rickets-x-linked-hypophosphatemia. Accessed 23 May 2024"},{"key":"1544_CR16","unstructured":"US Food and Drug Administration (2023) Fast track approvals. Previous Cumulative CY CDER FT Approvals. https:\/\/www.fda.gov\/drugs\/nda-and-bla-approvals\/fast-track-approvals. Accessed 23 May 2024"},{"issue":"3","key":"1544_CR17","doi-asserted-by":"publisher","first-page":"e001714","DOI":"10.1136\/rmdopen-2021-001714","volume":"7","author":"K Briot","year":"2021","unstructured":"Briot K, Portale AA, Brandi ML et al (2021) Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open 7(3):e001714. https:\/\/doi.org\/10.1136\/rmdopen-2021-001714","journal-title":"RMD Open"},{"issue":"4","key":"1544_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00223-022-01006-7","volume":"111","author":"ML Brandi","year":"2022","unstructured":"Brandi ML, de Beur SJ, Briot K et al (2022) Efficacy of burosumab in adults with X-linked hypophosphatemia (XLH): a post hoc subgroup analysis of a randomized double-blind placebo-controlled phase 3 study. Calcif Tissue Int 111(4):409\u2013418. https:\/\/doi.org\/10.1007\/s00223-022-01006-7","journal-title":"Calcif Tissue Int"},{"issue":"10189","key":"1544_CR19","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP et al (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393(10189):2416\u20132427. https:\/\/doi.org\/10.1016\/S0140-6736(19)30654-3","journal-title":"Lancet"},{"issue":"8","key":"1544_CR20","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA et al (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-fgf23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33(8):1383\u20131393. https:\/\/doi.org\/10.1002\/jbmr.3475","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1544_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale AA, Carpenter O, Brandi ML et al (2019) Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int 105(3):271\u2013284. https:\/\/doi.org\/10.1007\/s00223-019-00568-3","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"1544_CR22","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","volume":"108","author":"R Padidela","year":"2021","unstructured":"Padidela R, Whyte MP, Glorieux FH et al (2021) Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia. Calcif Tissue Int 108(5):622\u2013633. https:\/\/doi.org\/10.1007\/s00223-020-00797-x","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"1544_CR23","doi-asserted-by":"publisher","first-page":"e002676","DOI":"10.1136\/rmdopen-2022-002676","volume":"9","author":"P Kamenicky","year":"2023","unstructured":"Kamenicky P, Briot K, Brandi ML et al (2023) Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD Open 9(1):e002676. https:\/\/doi.org\/10.1136\/rmdopen-2022-002676","journal-title":"RMD Open"},{"issue":"3","key":"1544_CR24","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","volume":"107","author":"A Linglart","year":"2022","unstructured":"Linglart A, Imel E, Whyte MP et al (2022) Sustained efficacy and safety of burosumab, a monoclonal antibody to fgf23, in children with X-linked hypophosphatemia. J Clin Endocrinol Metab 107(3):813\u2013824. https:\/\/doi.org\/10.1210\/clinem\/dgab729","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1544_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/clinem\/dgac518","volume":"108","author":"TJ Weber","year":"2022","unstructured":"Weber TJ, Imel EA, Carpenter TO et al (2022) Long-term burosumab administration is safe and effective in adults with X-linked hypophosphatemia. J Clin Endocrinol Metab 108(1):155\u2013165. https:\/\/doi.org\/10.1210\/clinem\/dgac518","journal-title":"J Clin Endocrinol Metab"},{"key":"1544_CR26","first-page":"P13","volume":"95","author":"S Uday","year":"2023","unstructured":"Uday S, Jarvis C, Ramakrishnan R et al (2023) Cessation of burosumab treatment in adolescent patients with XLH: a multi-centre case series. Endocr Abstr 95:P13","journal-title":"Endocr Abstr"},{"issue":"1","key":"1544_CR27","doi-asserted-by":"publisher","first-page":"ziad001","DOI":"10.1093\/jbmrpl\/ziad001","volume":"8","author":"LM Ward","year":"2024","unstructured":"Ward LM, H\u00f6gler W, Glorieux FH et al (2024) Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period. JBMR Plus 8(1):ziad001. https:\/\/doi.org\/10.1093\/jbmrpl\/ziad001","journal-title":"JBMR Plus"},{"key":"1544_CR28","doi-asserted-by":"publisher","unstructured":"Baser O, Samayoa G, Yapar N et al (2023) Use of open claims vs closed claims in health outcomes research. J Health Econ Outcomes Res 10(2):44\u201352. https:\/\/doi.org\/10.36469\/001c.87538","DOI":"10.36469\/001c.87538"},{"issue":"1","key":"1544_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","volume":"31","author":"L Seefried","year":"2021","unstructured":"Seefried L, Smyth M, Keen R, Harvengt P (2021) Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review. Osteoporos Int 31(1):7\u201322. https:\/\/doi.org\/10.1007\/s00198-020-05548-0","journal-title":"Osteoporos Int"},{"issue":"2","key":"1544_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF00860736","volume":"9","author":"A Taylor","year":"1995","unstructured":"Taylor A, Sherman NH, Norman ME (1995) Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease. Pediatr Nephrol 9(2):173\u2013175. https:\/\/doi.org\/10.1007\/BF00860736","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"1544_CR31","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1210\/js.2018-00338","volume":"3","author":"GdPC Neto","year":"2019","unstructured":"Neto GdPC, Yamauchi FI, Baroni RH et al (2019) Nephrocalcinosis and nephrolithiasis in X-linked hypophosphatemic rickets: diagnostic imaging and risk factors. J Endocr Soc 3(5):1053\u20131061. https:\/\/doi.org\/10.1210\/js.2018-00338","journal-title":"J Endocr Soc"},{"key":"1544_CR32","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13023-023-02882-4","volume":"18","author":"G Ariceta","year":"2023","unstructured":"Ariceta G, Beck-Nielsen SS, Boot AM et al (2023) The international X-linked hypophosphatemia (XLH) registry: first interim analysis of baseline demographic, genetic and clinical data. Orphanet J Rare Dis 18:204. https:\/\/doi.org\/10.1186\/s13023-023-02882-4","journal-title":"Orphanet J Rare Dis"},{"key":"1544_CR33","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00198-021-05997-1","volume":"32","author":"S Giannini","year":"2021","unstructured":"Giannini S, Bianchi ML, Rendina D, Massoletti P, Lazzerini D, Brandi ML (2021) Burden of disease and clinical targets in adults patients with X-linked hypophosphatemia. A comprehensive review. Osteoporosis International 32:1937\u20131949. https:\/\/doi.org\/10.1007\/s00198-021-05997-1","journal-title":"Osteoporosis International"},{"issue":"2","key":"1544_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s13023-023-02883-3","volume":"18","author":"L Seefried","year":"2023","unstructured":"Seefried L, Alzahrani A, Sancho PA et al (2023) XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH). Orphanet J Rare Dis 18(2):333. https:\/\/doi.org\/10.1186\/s13023-023-02883-3","journal-title":"Orphanet J Rare Dis"},{"key":"1544_CR35","doi-asserted-by":"publisher","unstructured":"Lee B, Wang Y, Carlson SA et al (2023) National, state-level, and county-level prevalence estimates of adults aged \u2265 18 years self-reporting a lifetime diagnosis of depression \u2013 United States, 2020. MMWR Morb Mortal Wkly Rep 72(24):644\u2013650. https:\/\/doi.org\/10.15585\/mmwr.mm7224a1","DOI":"10.15585\/mmwr.mm7224a1"},{"issue":"2","key":"1544_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00223-021-00843-2","volume":"109","author":"B Abrahamsen","year":"2021","unstructured":"Abrahamsen B, Smith CD, Minisola S (2021) Epidemiology of tumor-induced osteomalacia in Denmark. Calcif Tissue Int 109(2):147\u2013156. https:\/\/doi.org\/10.1007\/s00223-021-00843-2","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"1544_CR37","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s00223-023-01148-2","volume":"113","author":"M May","year":"2023","unstructured":"May M, Oheim R, Bovy L et al (2023) Epidemiology of tumor-induced osteomalacia in Germany based on real world data. Calcif Tissue Int 113(6):630\u2013639. https:\/\/doi.org\/10.1007\/s00223-023-01148-2","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"1544_CR38","doi-asserted-by":"publisher","first-page":"e3436","DOI":"10.1210\/clinem\/dgac253","volume":"107","author":"D Rendina","year":"2022","unstructured":"Rendina D, Abate V, Cacace G et al (2022) Tumor-induced osteomalacia: a systematic review and individual patient\u2019s data analysis. J Clin Endocrinol Metab 107(8):e3436. https:\/\/doi.org\/10.1210\/clinem\/dgac253","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01544-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-025-01544-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-025-01544-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:16:59Z","timestamp":1766524619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-025-01544-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1544"],"URL":"https:\/\/doi.org\/10.1007\/s11657-025-01544-1","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript does not contain clinical studies, animal studies, or identifiable patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"This was a retrospective, descriptive analysis utilizing de-identified data from a claims database, and therefore did not require ethical review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"KMD has received research funding and consulted for Ultragenyx, Kyowa Kirin, Alexion, and received research funding from Regeneron and Sanofi. ZL and HH are employees of Kyowa Kirin, Inc. YZ is a former employee of Kyowa Kirin, Inc. AN is an employee of Komodo Health and JK a former employee of Komodo Health. EAI has received research funding and consulted for Ultragenyx and for Kyowa Kirin.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"64"}}